Company news

Incyte Corporation news in 2024

Incyte Corporation's news releases, calls and decks from 2024, newest first.

View company

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

December 9, 2024

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

December 6, 2024

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

November 25, 2024

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

November 24, 2024

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

November 17, 2024

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

October 28, 2024

Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List

October 23, 2024

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

October 9, 2024

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

September 24, 2024

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

September 17, 2024

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

September 13, 2024

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

September 13, 2024

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

August 20, 2024

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

August 14, 2024

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 13, 2024

Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 29, 2024

Incyte Announces Final Results of Tender Offer

June 12, 2024

Incyte Announces Preliminary Results of Tender Offer

June 10, 2024

Incyte Completes Acquisition of Escient Pharmaceuticals

May 29, 2024

Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings

May 20, 2024

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

May 13, 2024

Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock

May 12, 2024

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs

April 29, 2024

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

April 22, 2024

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

March 31, 2024

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

March 9, 2024

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

March 9, 2024

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

March 3, 2024

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

February 28, 2024

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

February 26, 2024

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities

February 12, 2024

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

February 4, 2024

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

January 22, 2024

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Calls in 2024

Decks in 2024